Abstract: A method of making a modified hyaluronate composition including providing an aqueous solution of uncrosslinked hyaluronic acid or sodium hyaluronate in unbuffered 135 to 200 mM NaCl, crosslinking the uncrosslinked hyaluronic acid or sodium hyaluronate in the aqueous solution with a dialdehyde or disulfide crosslinking agent to provide crude modified hyaluronate having a soluble fraction and a crosslinked fraction with a 10% to 98% degree of crosslinking, centrifuging the crude modified hyaluronate and removing at least a portion of the soluble fraction, and optionally repeating the centrifuging and removing until the modified hyaluronate has less than 10% by weight of the soluble fraction based on the total weight of hyaluronate, with a soluble fraction polydispersity (Mw/Mn) of 1 to 1.6, an Rh of the crosslinked fraction of 150 nm to 2000 nm, and an Rz of the crosslinked fraction of 50 nm to 700 nm, wherein Rh>Rz.

Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.

Abstract: A cosmetic composition for temporarily shaping hair includes, in a cosmetically acceptable support—respectively with respect to the total weight of the composition— e) from about 0.5% to about 8% by weight of a wax with a melting point of more than about 37° C., f) from about 0.5% to about 5% by weight of a fatty alcohol, g) from about 0.2% to about 2% by weight of a vinylpyrrolidone-containing polymer or copolymer, and h) from about 0.1% to about 10% by weight of composite powder comprising (A) powdered particles of a silicone elastomer, and (B) particles of silicon dioxide, wherein the particles of silicon dioxide (B) are immobilized on the surface of the powdered particles of the silicone elastomer (A).

Abstract: The present invention provides a 1,2,3-triazole derivative and an insecticide or acaricide containing the 1,2,3-triazole derivative as an active ingredient.

Abstract: Mixture of at least two esters selected from neopentylglycol dipelargonate, glycerol tripelargonate, pentaerythritol tetrapelargonate, and use thereof in cosmetic compositions for the care, the make-up, the protection from the sun and for the cleansing of the skin and skin appendages.

Abstract: Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof.

Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.

Abstract: The present disclosure provides a liquid eyeliner and a manufacturing method thereof. The liquid eyeliner includes following components by weight: acrylic acid octyl acrylamide copolymer or propylene ester octyl acrylamide copolymer ranging from 4-9%, propylene glycol provided ranging from 5-7%, ethylhexylglycerin ranging from 0.1-0.6%, butanediol ranging from 1.5-4%, sorbitan oleate ranging from 1-2%, emulsifier ranging from 1.4-2.2%, polydimethylsiloxane ranging from 6-9%, polyvinylpyrrolidone ranging from 3-4%, sorbitan sesquioleate ranging from 1.2-2%, butylated hydroxytoluene ranging from 0.1-0.2%, methylparaben ranging from 0.1-0.3%, propylparaben ranging from 0.05-0.15%, phenoxyethanol ranging from 0.6-1.2%, essence ranging from 0.1-0.3%, carbon black ranging from 1.5-2.8%, iron oxide black ranging from 30-45%, deionized water ranging from 22-30%, and plant extract ranging from 0.1-0.3%.

Abstract: Systems and/or methods of treating and/or preventing nail disorders are disclosed herein. Also, disclosed herein are systems and/or methods of improving the appearance of a nail. A preferred embodiment of the present invention comprises a method of treating and/or preventing a nail disorder in a subject comprising topically applying a composition comprising a poly(urea-urethane)polymer and/or a poly(urea-urethane) pre-polymer to a nail of said subject, thereby treating and/or preventing said nail disorder.

Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

Abstract: Disclosed is an efficacious, low-pH skin care composition that provides good sensory properties and has a low skin irritation potential. The low-pH composition includes an effective amount of a vitamin B3 compound and, optionally, one or more additional skin care actives to provide a skin health and/or appearance benefit. The low-pH composition also includes a pH buffer comprising lactic acid and sodium lactate, a polymer thickener comprising polyacrylate crosspolymer-6, and a silicone fluid having a kinematic viscosity of 100 cSt or less at 25° C. The pH of the low-pH composition can range from 2.0 to 5.0.

Abstract: Methods of synthesizing Bi2S3—CdS particles in the form of spheres as well as properties of these Bi2S3—CdS particles are described. Methods of photocatalytic degradation of organic pollutants employing these Bi2S3—CdS particles and methods of preventing or reducing microbial growth on a surface by applying these Bi2S3—CdS particles in the form of a solution or an antimicrobial product onto the surface are also specified.

Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

Abstract: A method of treating skin in need thereof is disclosed. The method can include topically applying to the skin a composition consisting of kakadu plum extract, glycerin, water, and optionally alcohol.

Abstract: Methods of providing sustained sterilization of thermoplastics; providing thermoplastics that have the capacity to dispense sodium fluoride, and, a method of providing sustained sterilization of thermoplastics and providing thermoplastics that have the capacity to dispense sodium fluoride, both from the same thermoplastic article.

Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

Abstract: The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.

Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.

Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.